
News|Articles|February 1, 2004
Extended-release formulation of oxymorphone effective for pain relief in osteoarthritis
The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Robyn Crosson, J.D., Navitus Health Solutions
2
Yesafili, an Eylea biosimilar, launches with a price of $1,445
3
A conversation about using GLP-1s to manage antipsychotic weight gain, with Mahavir Agarwal, M.D., Ph.D.
4
Ashley Holzworth-Nash, Pharm.D., Evernorth
5






















